Vivos Therapeutics Inc Stock Price, News & Analysis

Vivos Therapeutics (NASDAQ: VVOS) will present new clinical data at the World Sleep Congress in Rome from March 11-16, 2022. Dr. Seth Heckman, MD will lead the presentation on March 15, focusing on patient outcomes utilizing the Vivos Method for treating obstructive sleep apnea (OSA). The Vivos Method offers a non-surgical, effective solution, with 97% of patients achieving clinical objectives. The Medical Advisory Board, formed in October 2021, aims to enhance evidence-based practices in sleep medicine.

Vivos Therapeutics has filed a new U.S. patent application for enhanced clinical methods in treating obstructive sleep apnea (OSA) using its proprietary Vivos Method. Early data show a significant 58% improvement in Apnea Hypopnea Index (AHI) score reductions among patients treated with the revised protocols. This initiative is part of Vivos' Continuous Clinical Improvement Program aimed at refining treatment and optimizing patient outcomes. Currently, around 54 million Americans suffer from sleep apnea, highlighting the necessity for effective, non-invasive treatment alternatives.

Vivos Therapeutics (NASDAQ: VVOS) announced a significant surge in its Home Sleep Apnea Tests (HST) for the three months ending December 31, 2021.

Key metrics include an 18x increase in total HSTs, a 5.7x rise in the number of dentists administering these tests, and a 3x increase in average tests per dentist.

This performance led to a renegotiated agreement with SleepImage, reducing costs and establishing a recurring revenue model. With over one billion people suffering from sleep apnea, Vivos aims to leverage its new arrangement to improve patient access to treatments.

Vivos Therapeutics, Inc. (NASDAQ: VVOS) announced that its mmRNA device is now covered by Medicare, marking a significant milestone for the treatment of obstructive sleep apnea (OSA) and snoring. This acceptance by the Centers for Medicare & Medicaid Services (CMS) allows millions of Medicare beneficiaries to access this innovative non-surgical solution. The mmRNA device is designed to provide effective therapy for mild to moderate OSA, and enhances commercial insurance coverage prospects. Approximately 54 million Americans suffer from sleep apnea, with many undiagnosed.

Vivos Therapeutics (NASDAQ: VVOS) has officially registered its products with Health Canada, enabling local dentists to provide comprehensive solutions for obstructive sleep apnea (OSA). The initiative aims to enhance patient outcomes through clinical screening, diagnosis, and treatment with Vivos’ oral appliances. Approximately 25,000 Canadian dentists are expected to utilize Vivos products, which have been effective for over 22,000 patients worldwide. The company plans to expand its manufacturing capacity in Canada to support this initiative, responding to strong demand for its innovative therapies.

Vivos Therapeutics, Inc. will present at the Benzinga Global Small Cap Conference on December 9, 2021, at 1:55 PM EST. The company's executives, including Chairman Kirk Huntsman and CFO Brad Amman, will discuss its innovative treatment for mild to moderate obstructive sleep apnea (OSA) using the Vivos System. This system is a non-surgical solution proven effective for over 22,000 patients worldwide. Interested investors can register for a free spectator pass and view the presentation online.

Vivos Therapeutics reported a 38% increase in Q3 revenue to $4.5 million, with a total of $12.5 million for the first nine months of 2021. Appliance sales surged by 33% in Q3, totaling 2,996 units sold. The company received FDA 510(k) clearance for its mmRNA device, enhancing reimbursement prospects. Despite a slight decrease in dentist enrollments due to COVID-19, strategic partnerships and new training facilities position Vivos for future growth. Gross margin decreased to 70% from 78% year-over-year, while cash reserves stand at $28.5 million.

Vivos Therapeutics, Inc. (NASDAQ: VVOS) will present at the Q4 Virtual Investor Summit on November 17, 2021, at 11:45 am EST. The presentation features CEO Kirk Huntsman, CFO Brad Amman, and Investor Relations Officer Ed Loew. Investors can register for the event through the provided link and view a replay on Vivos’ website post-presentation. Vivos specializes in treatments for obstructive sleep apnea (OSA), promoting their innovative Vivos System as a non-surgical, cost-effective solution. The company has treated over 19,000 patients with their oral appliances.

Vivos Therapeutics, Inc. (NASDAQ: VVOS) will release its third-quarter financial results on November 15, 2021, after market close. The company will conduct a conference call at 5:00 p.m. ET on the same day to discuss the financial results and outline its growth strategy. Known for developing innovative treatments for obstructive sleep apnea, Vivos utilizes customized oral appliances in its Vivos System. The company has effectively treated over 19,000 patients globally, emphasizing its commitment to non-invasive solutions for OSA.